南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2014年
4期
500-503
,共4页
李洪生%吴湖炳%王巧愚%韩彦江%王全师
李洪生%吳湖炳%王巧愚%韓彥江%王全師
리홍생%오호병%왕교우%한언강%왕전사
膀胱癌%肿瘤分期%体层摄影术,发射型计算机%脱氧葡萄糖
膀胱癌%腫瘤分期%體層攝影術,髮射型計算機%脫氧葡萄糖
방광암%종류분기%체층섭영술,발사형계산궤%탈양포도당
bladder cancer%staging%tomography%emission-computed,deoxyglucose
目的:探讨18F-FDG PET/CT双时相显像在膀胱癌术前分期中的应用价值。方法2003年5月~2012年5月进行18F-FDG PET/CT检查的膀胱癌初诊患者73例,男54例,女19例,年龄58.7(41~80)岁。所有患者18F-FDG PET/CT常规全身显像后,口服40 mg呋塞米并多饮水,多次排尿,服呋塞米后约2 h憋尿充盈膀胱,再进行18F-FDG PET/CT盆腔延迟显像。所有患者于18F-FDG PET/CT检查后1周内进行手术治疗,将PET/CT与手术病理学检查结果进行对比分析,评价18F-FDG PET/CT双时相显像在膀胱癌术前分期中的应用价值。结果18F-FDG PET/CT双时相显像对膀胱癌原发灶的T分期与病理分期符合率为63.0%(46/73),其中pT4期膀胱癌的分期符合率为100%(7/7);另外检出75.0%(6/8)的淋巴结转移灶,100%(4/4)的远隔器官转移灶和100%(4/4)原发性第二种恶性肿瘤病灶。结论本研究结果表明18F-FDG PET/CT双时相显像在T分期方面,尽管对pTa、pT1、pT2、pT3期膀胱癌的T分期价值不大,但对pT4期膀胱癌的T分期可能有重要的应用价值;在膀胱癌的N分期、M分期及发现第二种原发癌方面也可能有重要的应用价值。
目的:探討18F-FDG PET/CT雙時相顯像在膀胱癌術前分期中的應用價值。方法2003年5月~2012年5月進行18F-FDG PET/CT檢查的膀胱癌初診患者73例,男54例,女19例,年齡58.7(41~80)歲。所有患者18F-FDG PET/CT常規全身顯像後,口服40 mg呋塞米併多飲水,多次排尿,服呋塞米後約2 h憋尿充盈膀胱,再進行18F-FDG PET/CT盆腔延遲顯像。所有患者于18F-FDG PET/CT檢查後1週內進行手術治療,將PET/CT與手術病理學檢查結果進行對比分析,評價18F-FDG PET/CT雙時相顯像在膀胱癌術前分期中的應用價值。結果18F-FDG PET/CT雙時相顯像對膀胱癌原髮竈的T分期與病理分期符閤率為63.0%(46/73),其中pT4期膀胱癌的分期符閤率為100%(7/7);另外檢齣75.0%(6/8)的淋巴結轉移竈,100%(4/4)的遠隔器官轉移竈和100%(4/4)原髮性第二種噁性腫瘤病竈。結論本研究結果錶明18F-FDG PET/CT雙時相顯像在T分期方麵,儘管對pTa、pT1、pT2、pT3期膀胱癌的T分期價值不大,但對pT4期膀胱癌的T分期可能有重要的應用價值;在膀胱癌的N分期、M分期及髮現第二種原髮癌方麵也可能有重要的應用價值。
목적:탐토18F-FDG PET/CT쌍시상현상재방광암술전분기중적응용개치。방법2003년5월~2012년5월진행18F-FDG PET/CT검사적방광암초진환자73례,남54례,녀19례,년령58.7(41~80)세。소유환자18F-FDG PET/CT상규전신현상후,구복40 mg부새미병다음수,다차배뇨,복부새미후약2 h별뇨충영방광,재진행18F-FDG PET/CT분강연지현상。소유환자우18F-FDG PET/CT검사후1주내진행수술치료,장PET/CT여수술병이학검사결과진행대비분석,평개18F-FDG PET/CT쌍시상현상재방광암술전분기중적응용개치。결과18F-FDG PET/CT쌍시상현상대방광암원발조적T분기여병리분기부합솔위63.0%(46/73),기중pT4기방광암적분기부합솔위100%(7/7);령외검출75.0%(6/8)적림파결전이조,100%(4/4)적원격기관전이조화100%(4/4)원발성제이충악성종류병조。결론본연구결과표명18F-FDG PET/CT쌍시상현상재T분기방면,진관대pTa、pT1、pT2、pT3기방광암적T분기개치불대,단대pT4기방광암적T분기가능유중요적응용개치;재방광암적N분기、M분기급발현제이충원발암방면야가능유중요적응용개치。
Objective To investigate the clinical value of dual-phase 18F-FDG PET/CT with oral diuretics in preoperative staging of bladder cancer. Methods The imaging data were analyzed of 73 patients with bladder cancer undergoing preoperative dual-phase 18F-FDG PET/CT with oral diuretic between May, 2003 and May, 2012. All the patients underwent whole-body PET/CT scan 60 min after intravenous injection of 270-350 MBq of 18F-FDG. Additional delayed pelvic PET/CT images were acquired after forced diuresis using oral furosemide (40 mg). All the patients underwent subsequent radical cystectomy, and 18F-FDG PET/CT findings were compared with the histopathologic results to evaluate the value of dual-phase 18F-FDG PET/CT in preoperative staging. Results The concordance rate of dual-phase FDG PET/CT-based bladder cancer staging with the histopathologic results was 63.0%in the 73 patients, and was 100%(7/7) for pT4 bladder cancers. With dual-phase FDG PET/CT, the detection rate was 75.0%(6/8) for lymph node metastases, 100%(4/4) for distant metastases, and 100%(4/4) for other concurrent primary malignancies. Conclusion Though with limited accuracy in T-staging of pTa, pT1, pT2, and pT3 bladder cancer, dual-phase FDG PET/CT has important clinical value in staging of pT4 bladder cancer and in N-staging, M-staging and detection of other concurrent primary malignancies.